| 09/01/2026 11:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 11:20 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/27/2026 6:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/25/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/19/2026 8:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Bezos… DOOMED (Ad) A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry.
James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. Watch James Altucher's free video breakdown before the September 25 deadline. |
| 08/17/2026 6:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/17/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/07/2026 10:40 AM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/03/2026 9:44 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/03/2026 9:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 5:54 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/14/2026 5:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 5:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/08/2026 3:30 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 1:30 PM | AstraZeneca (901832) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/29/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 5:05 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/16/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 5:52 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/29/2026 5:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 1:29 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 05/27/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:09 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 9:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:42 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/14/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/08/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad) In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night.
Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. See Jim Rickards' full market warning and what it means for your portfolio |
| 05/01/2026 9:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 6:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 10:32 AM | AstraZeneca (901832) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/28/2026 6:31 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 5:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/23/2026 5:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/09/2026 12:01 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/08/2026 1:20 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 04/02/2026 8:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 9:30 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/31/2026 6:48 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 7:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 6:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/19/2026 6:51 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 7:07 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 6:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 7:11 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:50 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/04/2026 8:14 AM | AstraZeneca (901832) Filer | Form CERT | |
| 03/03/2026 3:01 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 03/02/2026 11:00 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/26/2026 7:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 9:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 7:30 AM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 02/24/2026 5:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/24/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/20/2026 5:57 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 10:55 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/06/2026 8:48 AM | AstraZeneca (901832) Filed by Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject | Form SCHEDULE 13D/A | |
| 02/06/2026 8:54 AM | AstraZeneca (901832) Filed by Monopar Therapeutics (1645469) Subject | Form SCHEDULE 13G/A | |
| 02/03/2026 2:21 PM | AstraZeneca (901832) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/03/2026 6:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 12:26 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/30/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 7:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/22/2026 3:28 PM | AstraZeneca (901832) Filer | Form CERT | |
| 01/22/2026 3:22 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 01/22/2026 3:14 PM | AstraZeneca (901832) Filer | Form CERT | |
| 01/20/2026 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/08/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/02/2026 11:24 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 6:47 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Are you leaving Social Security money on the table? (Ad) Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix.
A tax strategy quietly costing you thousands every year… Social Security timing that leaves real money on the table… An estate plan that's years out of date… An income strategy that could be working twice as hard…
These aren't small details. For most, it can be the difference between a retirement that works… and one that slowly unravels. One conversation with the right person can surface exactly what's missing — and give you a clear picture of where you actually stand. Take the free 2-minute quiz to see where your plan stands. |
| 12/22/2025 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 6:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/19/2025 7:35 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/16/2025 5:42 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/16/2025 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 12:48 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/01/2025 10:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/01/2025 10:47 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 5:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |